Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
HHKEX:25913.28
HKD
+0.08
(+2.34%)
Guangzhou Innogen Pharmaceutical Group Co Ltd Class H
HKEX:2591
(Hong Kong Exchange)
Recent
price
3.28
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Quarterly Revenue
CNY
•
in mil. unless spec.Quarterly Earnings Per Share
CNY
•
in mil. unless spec.Quarterly Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- Guangzhou Innogen Pharmaceutical Group Co Ltd (2591.HK) is a China-based biopharmaceutical company principally engaged in the research, development, and commercialization of innovative therapies for diabetes and other metabolic diseases, including obesity, overweight conditions, and metabolic dysfunction-associated steatohepatitis (MASH). Founded in 2014 and headquartered at Room 409, Building H, Self-numbered Creative Building, No. 2 Tengfei Second Street, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangzhou, Guangdong Province, PRC, with operational offices in Shanghai, the company focuses on humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonists and related candidates targeting metabolic and central nervous system disorders; its core commercial product is Efsubaglutide Alfa (brand name: Diabegone), a GLP-1R agonist approved by China's National Medical Products Administration (NMPA) in January 2025 for type 2 diabetes (T2D) as monotherapy and in combination with metformin, commercially launched in China in February 2025, approved in Macau in June 2025, with biologics license applications (BLAs) submitted in a Southeast Asian country and planned for a Latin American country in the second half of 2025; pipeline candidates include YN014 (brain-specific target for Alzheimer's disease, IND submission planned first half of 2026), YN401 (beta-cells-specific target for type 1 and type 2 diabetes, IND 2025-2026), YN209 (liver-specific target for MASH, IND 2026), YN203 (GCGR for T2D, IND 2026), and YN202 (GHS-R for obesity/overweight, IND 2026), with Efsubaglutide Alfa advancing in Phase IIb/III trials for obesity/overweight in China (initiated March 2025, completion Q4 2026), Phase II in Australia (first patient August 2025), and Phase IIa for MASH planned in China and the U.S. in 2026 following FDA IND approval in March 2023 and NMPA IND in March 2025. The company conducts its primary operations in mainland China, generating RMB56.4 million in revenue for the six months ended June 30, 2025, from Efsubaglutide Alfa sales, with a commercialization team of 84 members; it operates as a subsidiary of KPC Pharmaceuticals, Inc., employs 105 staff, and CEO Qinghua Wang also serves as chairman. In recent developments, the company listed H shares on the Hong Kong Stock Exchange main board on August 15, 2025, raising approximately HK$683 million (net HK$634.7 million) through a global offering of 36,556,400 shares at HK$18.68, advised by Cooley LLP with Citic Securities and CICC as joint sponsors; it expanded operations via subsidiaries like Haikou Innogen Pharmaceutical Technology Co., Ltd. and Innogen Technology for production, sales, and R&D, initiated global expansion of Efsubaglutide Alfa, passed formal review for National Reimbursement Drug List (NRDL) negotiations, and reported increased R&D expenses to RMB99.1 million and selling/distribution costs to RMB44.0 million in H1 2025 amid commercialization ramp-up.
Company News
Innogen to Present Phase IIb ENLIGHT Study Results for Efsubaglutide Alfa at the 2026 ADA Scientific Sessions